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Randomized open label comparative study of  synbiotic versus  probiotic in 
children with acute diarrhea 
Dr.S.A.Ayisha, Institute of Pharmacology, Madras Medical College, Chennai 
Introduction : 
Acute Gastroenteritis is one of the most frequent diseases in the childhood that leads to severe 
dehydration and has no specific treatment. Probiotics are known to beneficially modulate several 
host functions, the most important of which are immune responses and intestinal barrier 
integrity. Lactobacillus is well described as a probiotic which reduces the number of days of 
hospitalization and also the severity. The overall goal of this study is to compare the efficacy 
synbiotic against probiotic in reducing the duration and frequency of acute diarrhoea in children.. 
Materials and methods :   
The study was conducted in the Medical Gastroenterology Outpatient department in the Institute 
of Child Health, Madras Medical College, Chennai between August 2013 to August 2014. 100 
children were randomized into 2 groups of 50 each by simple randomization. Group A received 
standard therapy of Oral Rehydration Salt with Tab.Zinc 20 mg along with synbiotic. Group B 
received Standard therapy with probiotic. Treatment period was one week and follow-up period 
one week per patient.  
 
Results : 
136 children were screened out of which 100 children were included in the study and all the 
children completed the study. Clinically Group A ( standard therapy with symbiotic) showed 
statistically significant reduction in the duration and frequency of diarrhea p<0.001) 
 
Conclusion: Synbiotic is effective in reducing the duration and frequency of acute diarrhoea 
in children when administered along with standard therapy. 
 
Keywords :Acute diarrhea,  synbiotic,  probiotics  
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Introduction 
Diarrhoeal disease is the second most common cause of deaths in children under 
five years of age (0.58 million or 11%).
1
 It is a major cause of childhood mortality and 
morbidity affecting about 1.7 to 5 billion of children worldwide.
2
   
 Diarrhoea is defined as a passage of three or more liquid or watery stools in a day.
3
 
Acute diarrhoea is diarrhoea less than 14 days in duration in a previously normal child 
usually due to infective etiology. The most common age is 6–24 months. In developing 
countries, children under three years old experience on average three episodes of diarrhoea 
every year.  
Diarrhoea is a major problem in early childhood and environmental conditions like 
poor sanitation are risk factors. In developing countries, diarrhoea is a leading cause of 
illness and death in children, creating a tremendous economic strain on healthcare costs.   
Diarrhoea is usually a symptom of gastrointestinal infection known as 
Gastroenteritis, which can be caused by a variety of viral, bacterial, and parasitic 
organisms. Infection is spread through contaminated food or drinking-water, or from 
person to person as a result of poor hygiene. 
Diarrhoea can cause dehydration and loss of electrolytes. Children, elderly and 
immunocompromised are at increased risk. Hence, dehydration must be treated promptly 
to avoid complications like organ damage, shock or coma. 
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Fluid replacement is the cornerstone of therapy for diarrhoea regardless of etiology. 
Dehydration is treated with oral rehydration therapy (ORT) when mild or with intravenous 
fluids when severe. Antibiotics and antimotility agents are not effective in acute diarrhoea. 
Zinc, a micronutrient at a dose of 20 mg improves absorption of ORS and helps in speedy 
recovery.
4
 The current government of India guidelines recommend low osmolarity ORS, 
zinc and continued feeding of energy dense foods in addition to breastfeeding in the 
management of diarrhoea.
5 
 Probiotics and synbiotics have been used in the treatment of diarrhoea. Probiotics 
have been shown to shorten the duration of diarrhoea.
6 Probiotics are microorganisms purported to 
have a health benefit on the host organism. They can interact with commensal bacteria and can also 
have a direct impact on the host.  Prebiotics are food products defined as nondigestible food 
ingredients that benefit the host by selectively stimulating the growth and/or activity of one 
or a limited number of bacteria in the colon and thus improve host health. 
Deviations in composition or function from the usual microbiota, known as dysbiosis, 
have been observed in certain disease
 
 states  like Atopy (allergy) and asthma, Coeliac 
disease, Colon cancer, Type I diabetes, Inflammatory bowel disease (IBD), Irritable bowel 
syndrome (IBS), GI infections, Antibiotic-associated diarrhoea (AAD) and probiotics and 
synbiotics have been tried in these conditions.
7 
Probiotics stimulate the mucosal immune mechanisms and beneficially modulate 
intestinal barrier integrity; Prebiotics increase the numbers of beneficial anaerobic bacteria 
and decrease the population of potentially pathogenic microorganisms. These phenomena 
are thought to mediate most beneficial effects, including reduction of the incidence and 
severity of diarrhoea, which is one of the most widely, recognized uses for probiotics. 
10 
 
Synbiotics are preparations in which probiotic organisms and prebiotics are combined, 
presumably to form a synergistic relationship. Synbiotics have been proved to reduce 
markers of intestinal inflammation in disease states and this might change the way in 
which the immune system recognizes the antigens present in the intestine.
 
 
 Only few studies regarding the use of probiotics and synbiotics in diarrhoea are 
available, this study has been undertaken to compare the efficacy of synbiotics with 
probiotics, when administered along with the standard therapy in reducing the frequency 
and duration of acute diarrhoea in children.  
. 
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Review of Literature 
Diarrhoea is defined as a change in the individual bowel habit resulting in more 
frequent and/or loose stools. It expresses an acute gastrointestinal inflammation (acute 
gastroenteritis). In childhood, gastrointestinal infection is the most common cause of acute 
diarrhoea worldwide.
8 
 Acute Gastroenteritis is one of the most frequent diseases in the childhood .The 
median incidence of diarrhoea for all children younger than 5 years of age was 3.2 
episodes per child per year. The incidence of diarrhoea was higher in younger children 
aged 6-11 months, with 4.8 episodes per child per year.
9 
Diarrhoea may be associated with a specific disease of the intestines or secondary 
to a disease outside the intestines. For instance, bacillary dysentery directly affects the gut, 
whereas diabetes mellitus causes neuropathic diarrhoeal episodes. 
Furthermore, diarrhoea can be considered as acute or chronic disease. Whether 
acute or chronic, diarrhoea has the same pathophysiologic causes that help identification of 
specific treatments. 
 
INCIDENCE AND PREVALENCE  
The epidemiology of diarrhoea varies in developed versus developing countries.
10
 
Diarrhoea is a major problem in day care centers and nursing homes, probably because 
early childhood and environmental conditions are risk factors. Food-borne bacterial 
infection is a major concern, as several major food poisoning episodes have occurred that 
were traced to poor sanitary conditions. 
 
12 
 
Dehydration from GI infections is the second leading cause of morbidity and 
mortality worldwide, especially in infants and children less than 5 years of age. The 
median incidence of diarrhoea for all children less than 5 years of age was 3.2 episodes per 
child per year. The incidence of diarrhoea was higher in younger children, with 4.8 
episodes per child per year among children ages 6 to 11 months in comparison with 1.4 
episodes per child per year for 4-year-olds. Younger children also had a higher risk for 
death from acute dehydrating diarrhoea. For children less than 1 year of age and those ages 
1 to 4 years, the median mortality rates were 8.5 and 3.8 per 1,000 children per year 
respectively.
11
 Diarrhoea still accounts for 1.6 to 2.5 million deaths annually. 
According to the National Center for Health Statistics, 51% of deaths caused by 
diarrhoeal illness were among patients older than 74 years of age, and 27% were among 
55- to 74-year- olds, while 11% were in those younger than 5 years.
12 
 
Aetiology 
The most common cause of diarrhoea is an infection of the intestines due to either 
a virus, bacteria, or parasite; a condition known as gastroenteritis. These infections are 
often acquired from food or water that has been contaminated by stool, or directly from 
another person who is infected. 
Viruses are now recognized as the leading cause of diarrhoea in the world, although 
in many cases an exact pathogen cannot be determined. In industrialized countries the most 
clinically significant agents in infant acute diarrhoea are viruses mainly group A rotavirus. 
Other viruses involved are human calicivirus (norovirus and sapovirus, formerly known as 
13 
 
Norwalk and Sapporo virus), astrovirus and enteric adenovirus (types 40 and 41), with 
some common features.
13
 
Most common bacteria are Campylobacter spp. And Salmonella spp., followed by 
Shigella, Yersinia and Escherichia coli. The major parasitic infections are Giardia, 
Entamoeba histolytica and Cryptosporidium. 
Other causes include food intolerance (lactose), reaction to medications (eg 
antibiotics), functional bowel disorders like Irritable bowel syndrome, Intestinal disease 
like Inflammatory Bowel disease, celiac disease. 
 
Pathophysiology 
Diarrhoea occurs when the volume of water and electrolytes present in the colon 
exceeds its capacity for absorption. This can be mainly due to an increase in the secretion 
and/or a decrease in the absorption level of the small intestine. Decreased intestinal 
absorption occurs as a result of intestinal damage or inflammation. Viruses causing 
diarrhoea infect selectively mature enterocytes, causing cell lysis and producing a decrease 
in disaccharidase activity and in mechanisms for active sodium and water absorption. The 
consequence is a malabsorptive or osmotic diarrhoea.
14 
Diarrhoea caused by bacterial infection is most frequently secretory. Bacteria can 
activate one of the intracellular pathways leading to intestinal secretion through 
enterotoxins. 
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TYPES OF DIARRHOEA 
Based on the duration
15 
1.Acute- less than 2 weeks in duration 
2.Persistent- 2-4 weeks duration 
3.Chronic-  more than 4 weeks duration 
 
Based on the mechanism 
1. Secretory diarrhoea 
Secretory diarrhoea means that there is an increase in the active secretion, or there 
is decreased absorption. There is little to no structural damage of the intestinal mucosa. 
The most common cause of this type of diarrhoea is a cholera toxin that stimulates the 
secretion of anions, especially chloride ions. Therefore, to maintain a charge balance in 
the lumen, sodium is carried with it, along with water. In this type of diarrhoea intestinal 
fluid secretion is isotonic with plasma even during fasting.
16
 It continues even when there 
is no oral food intake. 
2. Osmotic diarrhoea 
Osmotic diarrhoea occurs when too much water is drawn into the bowels. If a 
person drinks solutions with excessive sugar or excessive salt, these can draw water from 
the body into the bowel and cause osmotic diarrhoea. Osmotic diarrhoea can also be the 
result of maldigestion (e.g., pancreatic disease or Coeliac disease), in which the nutrients 
are left in the lumen to pull in water. Or it can be caused by osmotic laxatives (which work 
to alleviate constipation by drawing water into the bowels). 
15 
 
 In healthy individuals, too much magnesium or undigested lactose can produce 
osmotic diarrhoea and distention of the bowel. A person who has lactose intolerance can 
have difficulty absorbing lactose after an extraordinarily high intake of dairy products. 
 In persons who have fructose malabsorption, excess fructose intake can also 
cause diarrhoea. High-fructose foods that also have high glucose content are more 
absorbable and less likely to cause diarrhoea. Sugar alcohols such as sorbitol (often found in 
sugar-free foods) are difficult for the body to absorb and, in large amounts, may lead to 
osmotic diarrhoea. In most of these cases, osmotic diarrhoea stops when offending agent 
(e.g. milk, sorbitol) is stopped. 
3. Exudative diarrhoea 
Exudative diarrhoea occurs with the presence of blood and pus in the stool. This 
occurs with inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis, and 
other severe infections such as E. coli or other forms of food poisoning.
17  
4. Inflammatory diarrhoea 
Inflammatory diarrhoea occurs when there is damage to the mucosal lining or brush 
border, which leads to a passive loss of protein-rich fluids and a decreased ability to absorb 
these lost fluids. Features of all three of the other types of diarrhoea
 
can be found in this 
type of diarrhoea. It can be caused by bacterial infections, viral infections, parasitic 
infections, or autoimmune problems such as inflammatory bowel diseases. It can also be 
caused by tuberculosis, colon cancer, and enteritis. 
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Symptoms of dehydration in children include 
1. Dry mouth 
2. Dry tongue and lips 
3. Sunken eyes 
4. Decreased urine output. 
5. Irritability 
6. Lethargy 
Symptoms of severe dehydration in children
18
:  
1. Drowsiness 
2. Decreased urine output 
3. Pale or mottled skin 
4. Cold extremities. 
5. Rapid and shallow breathing 
 
Signs of severe dehydration 
1. Sunken anterior fontanelle 
2. Dry mucous membranes 
3. Sunken eyes 
4. Lack of tears 
5. Loss of skin turgor.19 
6. Delayed capillary refill  
7. Reduced muscle mass 
8. Peripheral edema  
17 
 
 
 MANAGEMENT OF DIARRHOEA 
Acute diarrhoea is usually self-limited
20
 Management is generally supportive. As 
water does not contain electrolytes, drinking water cannot replace the lost electrolytes in 
diarrhoea. However, the best treatment of acute diarrhoea in a child is the use of oral 
rehydration solution.
21 
WHO recommends zinc along with Oral rehydration therapy for 
treatment of acute diarrhoea in the developing countries. 
 
Oral Rehydration Therapy (ORT)    
ORS replaces the lost fluids and essential salts thus preventing or treating dehydration 
and reducing the complications. The glucose contained in ORS solution enables the 
intestine to absorb the fluid and the salts more efficiently. ORT alone is an effective 
treatment for 90-95% of patients suffering from acute watery diarrhoea, regardless of 
cause.
22
 This makes intravenous drip therapy unnecessary in all but the most severe cases. 
   The necessary components of glucose based ORT include glucose, sodium, 
potassium, chloride, and water. Glucose-based ORT takes advantage of glucose coupled 
sodium transport in the small bowel. Glucose enhances sodium and subsequently water 
transport across intestinal walls. In children with vomiting and diarrhoea, ORT may be 
given as 5mL every 2 to 3 minutes in a teaspoon or oral syringe. Nasogastric 
administration of ORT is an alternative method of administration in a child with persistent 
vomiting. After starting rehydration therapy, patients should be observed for a reversal of 
the signs of dehydration, increased stool consistency, and decreased stool frequency. 
18 
 
Maintenance rehydration requires sodium concentrations of 40 to 60 mEq/L, 
compared to 50 to 90 mEq/L for initial rehydration. ORT solutions with high sodium 
content may be alternated with water if a low-sodium fluid is not available. The 
maintenance phase should provide 100 to 150 mL/kg per day plus additional 
replacement for stool losses. 
Clear fluids, such as soda, apple juice should be avoided in both the rehydration 
and maintenance phase of dehydration. Those solutions are hyperosmolar and may 
draw free water into the gut lumen and cause hypernatremia. In addition, high glucose 
concentrations may produce osmotic diarrhoea. 
Glucose-based ORT primarily prevents dehydration without much influence on the 
duration of diarrhoea or stool volume; low-osmolarity ORT solutions (rice- or cereal-
based), however, reduce the diarrhoea stool number, volume, and frequency, as well as 
the duration of diarrhoea, and the replacement volume requirement. 
The efficacy of rice-based ORT solutions may be a result, in part, of their 
hypotonicity, which promotes intestinal water absorption.
23
 Also, slow rice hydrolysis 
allows some rice (glucose) absorption to take place before hydrolysis occurs. Starch 
and simple proteins provide more cotransport molecules with a lower intraluminal 
osmotic load, thus increasing fluid and electrolyte uptake by enterocytes and reducing 
stool losses. Therefore, a larger carbohydrate load can be given with rice solutions, 
resulting in a greater nutritional advantage. 
If ORT does not improve the fluid status and the patient continues to produce 
frequent, large-volume watery stools, close supervision with medical support is 
19 
 
warranted. Weight loss of 9% to 10% is considered severe and requires IV fluid 
replacement with Ringer lactate or normal saline. 
 
Intravenous fluid therapy is also indicated in patients with uncontrolled vomiting, 
the presence of a paralytic ileus, stool output greater than 10 mL/kg per hour, shock, or 
loss of consciousness. Rapid IV rehydration is preferred over more prolonged deficit-
replacement regimens for restoring extracellular fluids and electrolytes because it more 
effectively reestablishes gastrointestinal and renal perfusion.
24
 Early refeeding as 
tolerated is recommended. 
 
The American Academy of Pediatrics guidelines recommend age-appropriate diet 
resumption as soon as dehydration is corrected. Breast milk, lactose-free soy formula, 
and cow’s-milk-based formulas often can be continued. Early initiation of feeding has 
shortened the course of diarrhoea. In a study of severely malnourished children 
younger than 5 years of age with diarrhoea, using a standardized protocol of slower 
oral rehydration, immediate feeding, and intensive management of complications 
resulted in a significant reduction of mortality as compared with standard therapy. 
Initially, easily digested foods, such as bananas, applesauce, and cereal, may be added. 
Foods high in fiber, sodium, and sugar should be avoided. Lactase deficiency 
may be exacerbated among known lactase-deficient patients and may persist up to 10 
days. 
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ORAL REHYDRATION SOLUTION (ORS) - TYPES 
1. GLUCOSE BASED – ORS( Standard WHO ORS) : Total osmolarity of 311 
mmol/litre 
2. LOW- OSMOLARITY ORS- Total osmolarity of 245 mmol/litre 
3. CEREAL BASED ORS- Rice- based ORS 
4. ORS WITH OTHER NUTRIENTS (Glycine/Alanine) 
5. HOME-MADE ORS 
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FLUID THERAPY 
  PLAN A for ‘no dehydration’ 
 Provision of normal daily requirement of fluids and 
            Replacement of ongoing losses to prevent dehydration. 
Replacement is done with 
1.  Home available fluids 
• Solution made from Sugar and Salt ( Homemade) 
Sugar 40gm + Salt Nacl 4gm in 1 litre of water 
• Rice water with Salt ( Kanji) 
• Lassi with Salt  
• Coconut water 
• Dhal Water 
• Lemon Water. 
Fluids not suitable  
• Glucose water without Salt. 
• Fluids consumed on very small quantities such as tea, coffee. 
 
2. ORS 
  For children under 2 years, 50-100ml of ORS to be given after each stool. 100-200 
ml of ORS for children above 2 yrs 
 
22 
 
PLAN B for ‘Some dehydration’ 
    The Fluid therapy contains 3 components 
1) Rehydration therapy – correction of existing water and electrolytes deficit. 
2) Maintenance therapy – replacement of ongoing losses. 
3) Provision of normal daily requirements of fluids. 
Rehydration therapy 
Give 75ml/kg of ORS in the first 4 hours.  
 
PLAN C for ‘Severe dehydration’ 
    Children with severe dehydration should be given rapid IV rehydration. 
The best IV fluid is Ringer lactate (RL) solution. The ideal preparation would be ringer 
lactate with 5% dextrose. If RL is not available, normal saline 0.9% can be used. 
Give 100ml/kg of solution as follows. 
 
 
Monitoring: 
Reassess the hydration status every 15 minutes until a strong radial pulse is felt and 
when the full volume of iv fluid is over. 
 
      
In children < 12 months In older children 
First 30ml/kg in 1 hour First 20ml/kg in 30 minutes 
Then 70ml/kg in  5 hours Then 70ml/kg in 2.5 hours 
23 
 
Antimicrobial Therapy 
The indiscriminate use of antimicrobial therapy in GI infections produces increase 
in antimicrobial resistance, side effects of antimicrobial agents, and the threat of 
superinfections owing to eradication of normal flora. Increasing fluoroquinolone 
resistance in Campylobacter and multidrug resistance in Salmonella species worldwide 
reinforce the importance of judicious use of antibiotics and prudent infection control 
measures.
25,26 
 Furthermore, it stresses the need to take local susceptibility patterns into 
account in the selection of initial choice of antimicrobial regimen. 
Antibiotics are not essential in the treatment of most mild diarrhoeas, and empirical 
therapy for acute GI infections may result in courses of unnecessary antibiotics. 
However, appropriate antibiotic therapy shortens the duration of illness and reduces 
morbidity in some bacterial (cholera, enterotoxigenic E. coli, shigellosis, 
campylobacteriosis, yersiniosis) infections and can be lifesaving in invasive infections 
(C. difficile, salmonellosis). 
Antibiotic treatment also reduces the duration and shedding of organisms in 
infections with susceptible Shigella species and possibly in infection with susceptible 
Campylobacter species.
 
It is also important to note that outcomes of some bacterial diarrhoeal illnesses may 
be worsened by the use of antibiotics. Antibiotic treatment may prolong asymptomatic 
carriage of Salmonella.
27  
In patients infected with E. coli O157, use of an antimicrobial 
agent may worsen the risk of hemolytic uremic syndrome (HUS)
28
, which is defined by 
the triad of acute renal failure, thrombocytopenia, and microangiopathic hemolytic 
anemia, by increasing the production of shiga-like toxin.
29 
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     Antimotility Agents 
Antiperistaltic drugs such as diphenoxylate and loperamide
30 
offer symptomatic 
relief in patients with mild diarrhoea. However, these agents are contraindicated in 
most toxin-mediated diarrhoeal illnesses (enterohemorrhagic E. coli, 
pseudomembranous colitis, shigellosis) and thus should be avoided in patients with 
high fever and bloody diarrhoea. Slowing of fecal transit time is thought to result in 
extended toxin-associated damage. 
Feeding 
Early feeding may decrease the intestinal permeability changes induced by 
infection, reduce illness duration, and improve nutritional recovery.
31
 The 
recommendations after the period of rehydration are: 
• Continuation of breastfeeding in all cases. 
• In formula-fed infants continuation of a nondiluted formula, without restriction of 
lactose intake. 
• Resumption of full normal diet in older children, except for avoiding foods rich in 
simple sugars, due to its osmotic load. 
Micronutrients 
Zinc has been the main micronutrient implied in the diarrhoeal process. Studies 
performed in developing countries have shown its effectiveness in the treatment of 
acute and persistent diarrhoea in children younger than 5 years. This has led the WHO 
and UNICEF to recommend treatment with zinc in all children with diarrhoea in 
developing countries.
19
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Probiotics 
The addition of probiotics has shown to shorten the duration of the diarrhoea. A 
moderate clinical benefit of some probiotics has been shown in the treatment of acute 
watery diarrhoea, mainly by rotavirus in infants and young children.
6 
This effect seems 
to be: moderate in reducing diarrhoea by 17–30 hours; strain dependent with 
Lactobacillus GG most effective; not effective in bacterial invasive diarrhoea; effective 
when it is administered early in the disease to children in developed countries 
 
Synbiotics 
Synbiotics are combination of probiotics and prebiotics. They have been found to 
be effective in Irritable bowel syndrome, atopy and allergy, eradication of H.pylori, 
apthous ulcer.
7
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ZINC: 
1. Zinc is a micro-nutrient and promotes immunity. 
2. It is an important antioxidant and preserves cellular membrane integrity. 
3. Promotes the growth and development of the nervous system.  
4. Rich sources of Zinc are foods of animal origin, such as meat and fish. 
5. Zinc is also present in nuts, seeds, legumes, and whole grain cereal, but 
the high phytate content of these foods interferes with its absorption.  
6. Zinc cannot be stored in the body, and zinc excretion through the 
gastrointestinal tract is increased during episodes of diarrhoea.
32
  
MECHANISM OF ACTION: 
• Zinc reduces the fluid and salt loss in stools by improving mucosal permeability.33  
• Accelerated regeneration of mucosa 
• Increased levels of brush-border enzymes 
• Enhanced cellular immunity  
• Higher levels of secretory antibodies 
• Zinc improves absorption of ORS and reduces the severity and duration of illness.34 
• Reduces need for antibiotics.35 
• Reduces the chances of complications. 
• Full dose for 14 days protects against diarrhoea and pneumonia for next 3 months. 
• Acts as a general tonic-improves appetite and promotes growth 
27 
 
 
FORMULATIONS OF ZINC 
1. Zinc sulphate 
2. Zinc acetate 
3. Zinc gluconate 
 
DOSAGE OF ZINC: 
1. Less than 6 months- 10 mg/day 
2. More than 6 months- 20mg/day. 
 
DURATION OF TREATMENT: 2 weeks 
EFFICACY OF ZINC IN DIARRHOEA: 
• 15% faster recovery during the episode of diarrhoea.36 
• 16 % decrease in duration of diarrhoea.37 
• 24% decrease in frequency of episodes lasting more than 7 days. 
• 9-23% decrease in frequency of stools.38 
• Up to 31% reduction in stool output during the episode of diarrhoea 
• 42% reduction in treatment failure or death in persistent diarrhoea.39 
VENTION OF 
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SYNBIOTICS AND PROBIOTICS 
 
THE INTESTINAL MICROFLORA 
 The human intestines host at least 400 different bacterial species.
40
 Approximately 
55% of faecal mass consists of bacteria. Micro organisms from the mother and the 
environment colonize the gut of the infants after birth. 
Factors like mode of delivery, prematurity, hospitalization, use of antibiotics after 
birth and type of feeding influence the pattern of implantation of the beneficial microbes. 
The intestinal microflora are involved in various nutritional functions, such as 
breakdown of Indigestible dietary carbohydrates, production of short chain fatty acids 
(SCFA), synthesis of amino acids and vitamins. 
The intestinal micro flora plays a vital role in the development of local immune 
system. 
 
THE INTESTINAL MICROFLORA AND THE IMMUNE SYSTEM 
 Gut-associated lymphoid tissue (GALT) is the largest mass of lymphoid tissue 
found in the gastrointestinal tract.
41
 The GALT interacts with intestinal bacteria that are 
presented by dendritic cells through two types of receptors, Toll-like receptors (TLR) and 
nucleotiede-binding oligomerization domain (NOD) molecules. 
The intestinal microflora appears to be essential for the development of the GALT. 
Studies have shown that mice without microflora  have  poorly developed GALT with very 
few numbers of  intestinal intraepithelial lymphocytes , hypoplastic Peyer’s patches  with 
less germinal centres and  reduced numbers of  plasma cells that produces IgA. 
29 
 
 
SYNBIOTICS 
 Synbiotics are synergestic combination of probiotics and prebiotics that improves 
the survival and implantation of beneficial live microorganisms in the gastrointestinal tract 
of the host.
42 
 
Prebiotics 
 Prebiotics are non digestable food ingredients that selectively stimulates the growth 
and activity of bacterial species already established in the colon. 
Commonly used prebiotics are 
1. Oligofructose  
2.  Inulin 
3.  Galactooligosaccharides  
4.  Lactulose 
5. Breast milk. 
Lactulose is a synthetic disaccharide used as a drug for the treatment of 
constipation and hepatic encephalopathy. The prebiotic oligofructose is found naturally in 
many foods, such as wheat, onions, bananas, honey, garlic, and leeks. Oligofructose can 
also be isolated from chicory root or synthesized enzymatically from sucrose.  
Fermentation of oligofructose in the colon results in a large number of physiologic 
effects, including:  
 Increasing the numbers of bifidobacteria in the colon  
 Increasing calcium absorption  
30 
 
 Increasing fecal weight  
 Shortening gastrointestinal transit time  
 Possibly, lowering blood lipid levels  
 
The increase in colonic bifidobacteria has been assumed to benefit human health by 
producing compounds to inhibit potential pathogens, by reducing blood ammonia levels, 
and by producing vitamins and digestive enzymes.  
Any prebiotic should possess the following characteristics: 
 alter colonic flora towards healthier composition 
 stimulate the growth of beneficial bacteria commensal to the colon, by acting as 
their substrate selectively 
 neither get hydrolyzed nor absorbed in the upper part of GIT 
 inducing beneficial effects to the host luminally or systemically. 
 
Among the food ingredients, non digestable carbohydartes (oligo and 
polysaccharides), some peptides and proteins and certain lipids (both ethers and esters) are 
candidate prebiotics. Because of their chemical structure, these compounds are not 
absorbed in the upper part of GIT or hydrolyzed by human digestive enzymes, serving as 
substrates for the endogenous colonic bacteria, thus indirectly providing the host with 
energy, metabolic substrates and essential micro nutrients. 
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Sources of probiotics:
 43
 
 Soybeans 
 Jicama 
 Chicory Root 
 Raw Oats 
 Unrefined Wheat 
 Unrefined Barley 
 Breast Milk. 
 Mutated bacterial species of Clostridim butyricum, Streptococcus fecalis, Bacillus 
mesentricus 
 
MECHANISM OF ACTION OF PREBIOTICS: 
 Enhancing host immunity (IgA production, cytokine modulation, etc.)  
 Metabolic effects:  production of short-chain fatty acids, fat metabolism, absorption 
of ions (Ca, Fe, Mg)  
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Probiotics 
 Probiotics are live microorganisms administered in adequate amounts with 
beneficial health effects on the host. Eli Metchinikoff, the Ukranian born Nobel prize 
winner suggested that the dependence of the intestinal microorganisms on food makes it 
possible to modify the flora in our bodies and replace the harmful microbes by useful 
microbes. 
To improve the chances of survival in the intestine, a probiotic should be non 
pathogenic, non toxic and resistant to acidic pH and bile salts.
 
Probiotics should be able to: 
 survive intestinal pH 
 adhere to mucosa 
 colonize the intestine 
 produce antimicrobial substances 
 antagonize pathogenic bacteria 
 
Common sources of probiotics: 
 Yogurt 
 Kefir 
 Pickles 
 Fermented Kombucha Tea 
 Soy Beans 
 Dark Chocolate  
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MECHANISM OF ACTION OF PROBIOTICS:
44 
Immunologic benefits  
 Activate local macrophages to increase antigen presentation to B lymphocytes and 
increase secretory immunoglobulin A (IgA) production both locally and 
systemically  
 Modulate cytokine profiles  
 Induce hyporesponsiveness to food antigens  
 
Nonimmunologic benefits  
 Digest food and compete for nutrients with pathogens  
 Alter local pH to create an unfavorable local environment for pathogens  
 Produce bacteriocins to inhibit pathogens  
 Scavenge superoxide radicals  
 Stimulate epithelial mucin production  
 Enhance intestinal barrier function  
 Compete for adhesion with pathogens  
 Modify pathogen-derived toxins  
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IMPORTANT STRAINS IN PROBIOTIC FORMULATIONS: 
 Most important members in the probiotic formulations are  
1. Bifidobacteria  
2. Lactobacillus.  
3. Streptococcus 
4. Bacillus   
5. Clostridium  
6. Streptomyces  
7. Yeasts and moulds like Saccharomyces boulardii  
 
Lactobacillus species: 
 They are gram  positive , lactic acid producing bacteria. They are found mainly in 
the small intestine. Lactobacillus sporogenes is non pathogenic bacterium naturally 
occurring in intestine. It is responsible for synthesis of vitamin B complex and vitamin D 
and also responsible for synthesis of digestive enzymes. These spores proliferate in the 
small intestine and produce lactic acid which inhibits the enteric pathogenic organisms. 
Lactobacillus rhamnosus improves body immunity and prevents antibiotic associated 
diarrhoea .lacto bacillus reuteri is used in prevention of H.pylori and gingival infection. 
lactobacillus acidophilus and Lactobacillus plantarum are also used as probiotic 
supplements. 
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Bifidobacterium species 
 Bifidobacteria are gram positive , micro aerophillic that are highly prevalent in 
human intestines. Bifidobacterium  animalis and bifidobacterium longum are used in 
infantile diarrhoea 
 
Streptococcus faecalis 
 They are gram positive , aerobic , non spore forming cocci that proliferate with 
bacillus mesentricus and clostridium butyricum to produce lactic acid  which inhibit 
harmful bacteria. 
 
Clostridium butyricum 
 They are live gram positive spore forming bacilli producing butyric acid and acetic 
acid which decrease intestinal ph and prevents growth of harmful bacteria. 
 
Bacillus species: 
 Bacillus mesentricus and spores of Bacillus clausii have probiotic action. Live 
gram positive spore forming bacilli that produces an amylolytic enzyme and protease to 
activate proliferation of streptococcus. 
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USES OF PROBIOTICS  
GASTROINTESTINAL TRACT: 
Probiotics containing β galactosidase helps in improving lactose intolerance. Intake 
of  probiotics like Saccharomyces cerevisiae helps in degradation  of sucrose in children 
with sucrase deficiency . Deficiency of beneficial micro organisms and overgrowth of 
clostridium difficle are responsible for the occurrence of Antibiotic associated diarrhoea 
.Use of  Saccharomyces boulardii has been shown  to improve the condition by replacing 
the beneficial micro flora. 
Probiotics are also being used in prevention and treatment of Rotavirus associated 
diarrhoea.
45
 The effects are due to production of acids, hydrogen peroxide, antimicrobial 
substances, competition for nutrients or adhesion receptors, antitoxin actions and 
stimulation of immune system. Probiotics have also been found to be ffctive in antibiotic 
associated diarrhoea.
46 
Lactobacillus reduces the risk of colorectal cancer by reducing the activity of 
certain fecal enzymes which convert the procarcinogens to carcinogens. 
Eradication of Helicobacter pylori  
 Several lactobacilli and bifidobacterial strains, as well as Bacillus clausii47 appear 
to reduce the side effects of antibiotic therapies and improve patient compliance. Several 
strains were effective in decreasing side effects and increasing the eradication rates.
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Hepatic encephalopathy  
 Prebiotics such as lactulose are commonly used for the prevention and treatment of 
this complication of cirrhosis.  
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Irritable bowel syndrome (IBS)  
           Several studies have demonstrated significant therapeutic gains with probiotics in 
comparison with placebo. A reduction in abdominal bloating and flatulence as a result of 
probiotic treatments is a consistent finding in published studies; some strains may 
ameliorate pain and provide global relief (B. infantis 35624) in addition. Lactobacillus 
reuteri   improves colicky symptoms within one week.
49
 
 
UROGENITAL INFECTIONS: 
 L.rhamnosus  and L.reuteri strains when applied topically helps in prevention of  
urogenital infections.  
 
ATOPIC DISEASE:  
  Lactobacilli reduce the gut permeability, increases gut specific IgA response, 
promotes the barrier function of the intestines by restoring beneficial microbes to normal 
level. They also enhance the production of TGF-β and IL-10 and increase the level of 
cytokines that promote the production of IgE antibodies. 
 
OROPHARYNGEAL INFECTIONS 
 α-Hemolytic Streptococci have an interfering activity against pathogens that cause 
otitis media. 
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EFFECT ON CANDIDIAL INFECTIONS 
 Probiotics reduce the prevalence of oral candidiasis and risk of hyposalivation in 
elderly. 
 
APHTHOUS ULCER 
 Probiotics are beneficial in treatment of recurrent aphthous ulcers of the mouth. 
The ability of lactobacillus to increase the activity of phagocytes must be the key factor in 
combating recurrent aphthous ulcer.
50
 
 
HALITOSIS 
 Probiotics prevent the growth of odour causing organisms and hence used  in the 
treatment and prevention of halitosis. 
 
This study is undertaken to compare the efficacy of synbiotic with probiotic in 
acute diarrhoea in children. 
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OBJECTIVE 
 
 To evaluate the safety, efficacy and tolerability of synbiotic against probiotic in 
reducing the episodes (frequency) and the duration of acute diarrhoea. 
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METHODOLOGY 
 
Study design: 
 A randomized open label comparative study 
 
Study population:  
 Children aged 6 months- 5 yrs with acute diarrhoea  
 
Study Center:  
 Institute of Pharmacology in collaboration with 
 Out-patient department of  Medical Gastroenterology, Institute of Child Health, 
Madras Medical College, Chennai. 
 
Study period:  
 August 2013 to August 2014 
 
Study duration: 2 weeks 
 1 week of treatment + 1 week follow-up per patient. 
 
Sample size:  
 100 (Group A-50, Group B-50) 
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Eligibility criteria 
Inclusion criteria: 
 Age – 6 months- 5 yrs  
 Sex - both genders 
 Children with acute diarrhoea ( less than 14 days duration ) 
 Parents willing to give written informed consent. 
 
Exclusion criteria 
 Children with Persistent diarrhoea 
 Children with severe dehydration 
 Children with severe malnutrition 
 Children having respiratory / systemic infection 
 Subject who participated in any investigational drug within 30 days prior to study 
screening 
 Children with known hypersensitivity for synbiotics or probiotics 
 Children with chronic systemic illness 
 Parents not willing to give written informed consent. 
 
 
 
 
 
 
42 
 
 
STUDY PROCEDURE:  
 The study was conducted after obtaining the approval from Institutional Ethics 
Committee. Parents of children aged 6months to 5 years with acute diarrhoea attending the 
outpatient department of Medical Gastroenterology, Institute of Child Health, Madras 
Medical College were explained about the study purpose and procedures.  
 
 Written informed consent was obtained from the parents, in the prescribed format 
in regional language prior to the performance of any study related procedures. If the parent 
was illiterate, left thumb impression was sought. This was done in the presence of an 
impartial witness. The demographic details of the patients were obtained and recorded. 
Children were screened by complete medical history, clinical examination and 
laboratory investigations. Subjects who fulfilled the inclusion and exclusion criteria were 
enrolled in the study and randomized to either Group A or Group B. 
 
 
RANDOMIZATION: 
 The enrolled patients were randomized by simple randomization into either group 
A or B. 
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TREATMENT PLAN: 
 GROUP A (n=50):  
Standard treatment plus synbiotic 5 ml twice daily for 1 week 
GROUP B (n=50):  
Standard therapy plus probiotic 5 ml twice daily for 1 week 
 
STANDARD THERAPY   
 Oral  rehydration  therapy 
 Tab.Zinc sulphate 20 mg one tablet daily for 2 wks plus 
 
 SYNBIOTIC                                                                            
 
  Composition of Synbiotic: per 5 ml 
1. Streptococcus faecalis T-110 -   30 million 
2. Clostridium butyricum TO-A-    2 million 
3. Bacillus mesentricus TO-A –     1 million 
4. Lactobacillus sporogenes-          50 million 
Dosage: Dry syrup made upto 50 ml by adding water. 5 ml to be taken orally twice a day. 
The constituted solution must be used within five days and the remaining discarded. 
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 PROBIOTIC 
  Composition per 5 ml 
1. Bacillus clausii-  2 billion spores / vial 
Dosage-  One vial twice daily for 1 week. Each vial contains 5 ml. Contents of the vial 
to be emptied and taken orally. 
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STUDY FLOW CHART 
SCREENING 
Complete medical history, 
Clinical examination, 
Biochemical investigation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY COMPLETION-DATA  
ANALYSIS 
ENROLLMENT 
 
        GROUP A 
n=50 
        GROUP B 
n=50 
RANDOMIZATION 
Standard Treatment  
                         plus 
 Probiotic 5 ml  twice daily for 1 week 
 
Standard Treatment 
plus  
   Synbiotic 5 ml twice daily for 1 week 
FOLLOW UP -1 week 
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Visit 1 – Screening and enrollment 
 Informed consent obtained 
 Demographic details obtained 
 Randomization done 
 Medical history obtained 
 Vital signs recorded 
 General & systemic examination done 
 Assessment of Diarrhoea done 
 Lab Investigations done   
 Study medications given for 3 days 
 Parents  asked to return empty cartons during subsequent visits  
 
 
Visit 2 (Day 3) 
 Empty cartons received and compliance checked 
 Vital signs recorded 
 General & systemic examination done 
 Assessment of Diarrhoea done 
 Adverse events if any monitored  
 Study medications given for 4 days 
 Parents  asked to return empty cartons during subsequent visits  
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Visit 3 (Day 8) 
 Empty cartons received and compliance checked 
 Vital signs recorded 
 General & systemic examination done 
 Assessment of Diarrhoea done 
 Adverse events if any monitored 
 
Visit 4 (Day 16) 
 Vital signs recorded 
 General & systemic examination done 
 Investigations performed 
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The following laboratory investigations for Assessment of Diarrhoea were performed in 
the children at Day 1 and Day 16.  
Investigations: 
 Haematology 
 Haemoglobin 
 RBC Count 
 Total leucocyte count Differential count 
 Platelet count 
 Blood sugar 
 Blood Urea  
 Serum creatinine 
 Serum electrolytes 
 Liver function test 
 SGOT 
 SGPT 
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ASSESSMENT OF DIARRHOEA:  
      The severity of dehydration- no dehydration, some dehydration, severe dehydration 
 Diarrhoea- frequency and duration. 
Feeding practices 
Any concurrent illnesses like Pneumonia, otitis media 
 
ASSESSMENT OF DEHYDRATION 
Severe dehydration: 
 Two of the following signs have to be present 
        Lethargy or unconsciousness 
        Sunken eyes 
        Not able to drink or drinking poorly 
         Skin pinch goes back very slowly 
Some dehydration 
Two of the following signs have to be present: 
      Restlessness or irritability 
      Sunken eyes 
      Drinks eagerly 
     Skin pinch goes back slowly 
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No dehydration 
Two of the following signs has to be present: 
   Well, alert child 
   Eyes normal 
Drinks normally, not thirsty 
Skin pinch goes back quickly  
 
Recovery & Follow up: 
. Recovery is defined as the passage of first semi solid stools or no stools in the 
previous 18hrs. The findings were recorded in a pre-designed proforma and the parent was 
asked to bring the child for follow up after 1 week.   
Adverse drug effects: 
 Parents were advised to report as soon as possible in case of any adverse drug 
reactions (ADR) or occurrence of other illness or consumption of concomitant 
medications. Any adverse event observed or reported by the parent was recorded.  
 Causality assessment of adverse drug reactions was done using WHO scale. 
Severity assessment done by Modified Hartwig Seigel severity assessment scale. 
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WHO- Causality assessment scale: 
Causality term Assessment criteria 
 
Certain  
Event or a laboratory test abnormality with plausible time 
relationship to drug intake. 
Cannot be explained by disease or other drugs. 
Response to withdrawal plausible 
Event definitive pharmacologically or phenomenologically. 
Rechallenge satisfactory, if necessary 
 
Probable/likely 
Event or a laboratory test abnormality with reasonable time 
relationship to drug intake 
Unlikely to be attributed to disease or other drugs 
Response to withdrawal clinically reasonable 
Rechallenge not required. 
 
Possible  
Event or a laboratory test abnormality with reasonable time 
relationship to drug intake 
Cold also be explained by disease or other drugs. 
Information on drg withdrawal may be lacking or unclear 
 
Unlikely  
Event or a laboratory test abnormality with a time to drug 
intake that makes a relationship improbable 
Disease or other drugs provide plausible explanations 
Conditional / unclassified Event or a laboratory test abnormality with a time to drug 
intake that makes a relationship impossible. 
More data for proper assessment needed 
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MODIFIED HARTWIG SIEGEL SCALE: 
 
 
 
 
Mild 
 
Level 1 
 
No change in treatment required because of ADR. 
 
Level 2 
 
Drug changed /  discontinued 
No change in treatment required because of ADR, 
no increase in duration of hospital stay. 
 
 
Moderate 
 
Level 3 
 
Drug changed / discontinued, treatment required 
but no increase in duration of hospital stay. 
 
Level 4a 
 
Level 3+ increase in duration of hospital stay by 
atleast one day. 
 
Level 4b 
 
ADR is the reason for admission. 
 
 
Severe 
 
Level 5 
 
Level 4 requiring intensive medical care. 
 
Level 6 
 
ADR causing permanent harm 
 
Level 7 
 
ADR causing death directly/ indirectly. 
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STATISTICAL ANALYSIS: 
 The obtained data was analyzed statistically.  Distribution of age was analysed 
using ANOVA and Sex distribution was analyzed by Chi square test. 
 
 The biochemical investigations were performed on Day 1 and Day 16. The 
difference within the groups before and after treatment were analyzed using  
student’s paired t-test whereas the difference between the Groups A and B were analyzed 
using One Way ANOVA.  
 
 The difference within the groups in diarrhoea were analyzed using  
student’s paired t-test whereas the difference between the groups A and B in Diarrhoea 
assessement were analyzed using One way ANOVA.  
  
 p < 0.05 is considered to be statistically significant. 
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RESULTS 
 
 This study was conducted to evaluate the safety, efficacy and tolerability of 
synbiotic against probiotic in reducing the episodes (frequency) and the duration of acute 
diarrhoea in children. 
             136 children were screened, of which 36 were excluded from the study as they had 
severe dehydration. 
 All the 100 children completed the study. There were no dropouts.   
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EXCLUDED – 36 
 
 
 
   
SCREENED - 136 
ENROLLED - 100 
RANDOMIZATION 
CONTROLGROUP 
N =50 
TEST GROUP 
N = 50 
 
STATISTICAL ANALYSIS 
 
100 PATIENTS COMPLETED THE 
STUDY 
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Table –1 : AGE DISTRIBUTION 
                         
 
 
AGE  
 
GROUP A 
 
GROUP B 
 
NO 
 
PERCENTAGE 
 
NO 
 
PERCENTAGE 
 
6months- 2 years 
 
42 
 
84% 
 
46 
 
92% 
 
2-5 years 
 
8 
 
16% 
 
4 
 
8% 
 
 Table 1 shows the age distribution of both the groups. 
 42 (84%) children in group A and 46(92%) in Group B were in the age 
group of 6 months to 2 years 
 8 (16%) children in group A and 4(8%) in Group B were in the age group of 
2 to 5 years 
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FIGURE 1: AGE DISTRIBUTION 
 
 
 
 Figure 1 depicts age distribution in both the groups. 
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TABLE 2: MEAN AGE DISTRIBUTION 
 
GROUPS 
 
(No of 
patients) 
MEAN AGE 
( in months ) 
SD p VALUE 
GROUP A 50 16 15.8 
0.278 
GROUP B 50 17 15.8 
 
Table -2 shows the Age distribution of patients among both the groups 
 The mean age of patients in Group A is 16 months and Group B is 17 months. 
 There is no statistically significant difference in age between Group A and 
Group B. 
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FIGURE 2: MEAN AGE DISTRIBUTION 
 
 
Fig 2 shows the distribution of age in Group A and Group B 
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Table -3: GENDER DISTRIBUTION 
 
 
 
 
 
SEX 
DISTRIBUTION 
 
 
GROUPS 
 
 
GROUP A 
 
 
GROUP B 
 
n 
 
 
% 
 
n 
 
% 
MALE 31 62% 32 64% 
FEMALE 19 38% 18 36% 
TOTAL NO. OF 
PATIENTS 
50  50  
 
                    Table -3 shows the distribution of male and female patients of two groups 
 In Group A, 31(62%) patients were male and 19 (38%) patients were female. 
 In Group B, 32(64%) patients were male and 18(36%) patients were female.  
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Fig -3: GENDER DISTRIBUTION 
 
 
 
Fig 3 is the graphical representation of Table 3 
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Table 4: FREQUENCY OF DIARRHOEA  
 
GROUPS DAY 1 DAY 3  
p value MEAN  
 
SD MEAN 
 
SD 
GROUP A 9.03 3.41 0.81 1.01 
 
<0.0001 
GROUP B 10.1 4.42 6.24 3.32 0.006 
p value 0.42 0.02  
 
                        Table – 4 shows the mean frequency of diarrhoea  
 
 On comparing within the groups, there was a statistically significant reduction in 
the frequency of diarrhoea on day 3. 
 On comparing between the groups, there was no statistically significant difference 
at baseline.  
            There was a statistically significant difference between the groups on day 3 
            (p< 0.02). 
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Fig –4 : FREQUENCY OF DIARRHOEA 
 
 
                Fig 4 shows graphical representation of frequency of diarrhoea among Group A 
and B 
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Table -5: DURATION OF DIARRHOEA 
 
GROUPS Duration in hours 
MEAN SD 
GROUP A 36.2 12.3 
GROUP B 72.6 31.2 
p value 0.001 
 
               Table – 5 shows the mean duration of diarrhoea among group A and B 
 
On comparing the two groups, 
 
                                  There was a statistically significant reduction in the duration of 
diarrhoea (p<0.001). 
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Fig –5 : DURATION OF DIARRHOEA 
 
 
 
Fig 5 shows graphical representation of duration of diarrhoea among 
Group A and B. 
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Table 6: HYDRATION STATUS 
 
 
 
NO. OF CHILDREN  
 
 
GROUPS 
 
 
GROUP A 
 
 
GROUP B 
 
n 
 
 
% 
 
n 
 
% 
WITH SOME 
DEHYDRATION 
21 42% 24 48% 
WITHOUT 
DEHYDRATION 
29 58% 26 52% 
TOTAL NO. OF 
CHILDREN 
50  50  
 
Table 6 shows the hydration status of children in both groups 
On comparing the two groups,  
 In Group A, 21 (42%) children had some dehydration and 29 (58%) had no 
dehydration. 
 In Group B, 24(48%) children had some dehydration and 26 (52%) had no 
dehydration 
 None of the children had dehydration on day 3 in both the groups 
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Fig –6: HYDRATION STATUS 
 
 
 
Fig 6 shows graphical representation of hydration status among 
Group A and B 
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Table 7: HEMATOLOGICAL PARAMETERS 
 
 
Table7 shows the haematological and biochemical parameters on Day 1 and at Day 
16  in  Groups A and B. The differences in lab parameters were not statistically significant 
in both the groups. 
  
PARAMETER 
GROUP A GROUP B 
Day 1 Day 16 p VALUE Day 1 Day 16 pVALUE 
RBC COUNT 
Cells/cumm 
3.5 million 3.6 million 0.43 
3.6 
million 
3.5 million 0.45 
TOTAL COUNT 
Cells/cumm 
11557 11465 0.79 12043 11876 0.87 
HAEMOGLOBIN 
In g/dl 
11 11 0.55 11.5 11.5 0.71 
PLATELET 
COUNT 
Cells/cumm 
360000 350000 0.37 360000 370000 0.47 
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Table 8: RENAL FUNCTION TEST 
 
Table 8 shows the results of renal function test on Day 1 and at Day 16  in  Groups 
A and B. The differences in lab parameters were not statistically significant in both the 
groups. 
 
 
PARAMETER 
GROUP A GROUP B 
Day 1 Day 16 
p 
VALUE 
Day 1 Day 16 
P 
VALUE 
BLOOD 
SUGAR 
mg/dl 
105 110 0.9 106 109 0.21 
BLOOD UREA 
mg/dl 
21 21 0.65 22 22 0.79 
SERUM 
CREATININE 
mg/dl 
1 1 0.52 1 1 0.55 
SERUM 
SODIUM 
mEq/L 
137 138 0.32 138 137 0.36 
SERUM 
POTASSIUM 
mEq/L 
4 4.2 0.36 4.1 4.3 0.33 
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Table 9: LIVER FUNCTION TEST 
 
 
Table 9 shows the results of liver function test on Day 1 and at Day 16  in  Groups 
A and B. The differences in lab parameters were not statistically significant in both the 
groups. 
 
 
 
 
  
PARAMETER 
GROUP A GROUP B 
Day 1 Day 16 
p  
VALUE 
Day 1 Day 16 
 
 
p 
VALUE 
SGOT 
IU/L 
34 36 0.33 35 34 0.45 
SGPT 
IU/L 
43 43 0.68 45 46 0.78 
BILIRUBIN 
mg/dl 
1.1 1.1 0.97 1.1 1.1 0.92 
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Fig 7: RBC  COUNT 
 
                  Fig 7 shows the difference in RBC count in a graphical way.    
Fig 8:  HAEMOGLOBIN 
 
                      Fig 8 shows the difference in haemoglobin between  Group A and  B 
 
2.5
2.75
3
3.25
3.5
GROUP A GROUP B
3.6
3.53.5
3.6
R
B
C
c
o
u
n
t
m
i
l
l
i
o
n
c
e
l
l
s
/
c
u
.
m
m
Day 1
Day 16
9
9.5
10
10.5
11
11.5
12
Group A Group B
11
11.5
11
11.5
H
e
m
o
g
l
o
b
i
n
g
/
d
l
Day 1
Day 16
72 
 
                  
                                      Fig 9: TOTAL COUNT 
1  
                                    Fig 9 shows the difference in Total count in a graphical way. 
Fig 10: PLATELET COUNT 
 
Fig 10 shows the difference in Platelet count in a graphical way. 
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Fig 11: BLOOD SUGAR 
 
Fig 11 is the diagrammatic representation of mean blood sugar values in both groups 
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Fig 12 :BLOOD UREA 
 
The mean blood urea levels in both groups is represented in Fig 12 
 
Fig 13 :SERUM CREATININE 
 
Fig 13 is the graphical representation of mean serum creatinine values in both groups 
before and at the end of treatment 
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Fig 14: SERUM SODIUM 
 
                          The mean serum sodium  levels in both groups is represented in Fig 14 
  
Fig 15 :SERUM POTASSIUM                  
 
         The mean serum potassium levels in both groups is represented in Fig 15. 
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Fig 16: SGPT 
 
 
The mean SGPT values in both groups is represented in Fig 16 
Fig 17: SGOT 
 
Fig 17 shows the mean SGOT values in Group A and B 
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TABLE 10: ADVERSE EVENTS 
ADVERSE EVENTS GROUP A GROUP B 
VOMITING 5 5 
RASH 0 1 
FATIGUE 8 7 
ABDOMINAL PAIN 6 5 
 
 Table 10 shows the Adverse events reported in both groups. The adverse events 
were mild and no serious adverse effects were reported. There were no drop outs due to 
adverse events. Among the adverse events, it was found that fatigue was the most common 
followed by abdominal pain, vomiting and rash.    
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Fig 18: Adverse events 
 
 
Fig 18 shows number of Adverse events in both groups 
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TABLE 11: INCIDENCE OF ADRs 
 
 GROUP A GROUP B 
NUMBER OF 
ADRs 
19 18 
 
 Table 11 shows the incidence of ADRs presented by the patients in both the groups. 
 In Group A, 19 ADRs were reported and in Group B, 18 ADRs were reported. 
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FIGURE 19: INCIDENCE OF ADRs 
 
Figure 19 shows the graphical representation of incidence of ADRs.  
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TABLE 12 : CAUSALITY ASSESSMENT OF INDIVIDUAL ADR IN GROUP A 
 
ADRs 
 
Certain 
 
Probable 
 
Possible 
 
 
Un-likely 
 
Un- 
classified 
 
Un- 
classifiable 
 
Total 
 
Fatigue  
 
- 
 
- 
 
8 
 
- 
 
- 
 
- 
 
8 
 
Abdomin
al pain 
 
- 
 
 
- 
 
6 
 
- 
 
- 
 
- 
 
6 
 
Vomiting  
 
- 
 
- 
 
5 
 
- 
 
- 
 
- 
 
5 
 
Rash  
 
- 
 
- 
 
0 
 
- 
 
- 
 
- 
 
0 
 
Total 
   
19 
    
19 
 
 Table 12 shows causality assessment of individual ADR in Group A. 
 Causality assessment was done using WHO causality assessment scale 
 All adverse drug reactions were categorized as possible. 
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TABLE 13 : CAUSALITY ASSESSMENT OF INDIVIDUAL ADR IN GROUP B 
 
ADRs 
 
Certai
n 
 
Probabl
e 
 
Possible 
 
 
Un-likely 
 
Un- 
classified 
 
Un- 
classifiable 
 
Total 
 
Fatigue 
 
- 
 
- 
 
7 
 
- 
 
- 
 
- 
 
7 
 
Abdominal 
pain 
 
- 
 
- 
 
5 
 
- 
 
- 
 
- 
 
5 
 
Vomiting 
 
- 
 
- 
 
5 
 
- 
 
- 
 
- 
 
5 
 
Rash 
 
- 
 
- 
 
1 
 
- 
 
- 
 
- 
 
1 
 
Total 
   
18 
    
18 
 
 Table 13 shows causality assessment of individual ADR in Group B. 
 All ADRs were categorized as possible under WHO causality assessment scale. 
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TABLE 14: SEVERITY ASSESSMENT OF ADR 
 
 
SEVERITY 
 
GROUP A 
 
GROUP B 
 
MILD 
 
19 
 
18 
 
MODERATE 
 
-- 
 
-- 
 
SEVERE 
 
-- 
 
-- 
  
 Table 14 shows severity assessment of Adverse Drug Reactions. 
 Severity assessment was done using Modified Hartwig and Siegel scale. 
 All the Adverse Drug Reactions in both the groups were mild. 
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DISCUSSION 
Diarrhoea is a change in the individual bowel habit resulting in more frequent 
and/or loose stools. Diarrhoea can be considered as acute or chronic disease. 
Acute diarrhoea is a self-limiting process. The most common age is between 6–24 
months and when untreated diarrhoea can lead to dehydration, acidosis, and electrolyte 
imbalance. 
The only treatment necessary is replacing fluid loss and electrolytes to correct 
dehydration. Fluid replacement is done by administration of oral rehydration solution and 
intravenous fluids if necessary. Synbiotic and Probiotic may help in reducing the frequency 
and duration of the diarrhoea.     
 The study was conducted to assess the safety and efficacy of synbiotic and 
probiotic in acute diarrhoea in children. 100 children were randomized into two groups and 
received either synbiotic or probiotic along with standard therapy. 
The enrolled subjects were assessed on day 3 and day 8 by clinical examination. 
Lab investigations were done on day 1 and day 16. Data were compiled and results 
analyzed statistically. 
There was no significant difference in the mean age of children in both groups in 
this study. This shows that the age distribution was similar in both the groups. Males were 
more in number than females in both the groups. This was similar to the study conducted 
by Huang JS et al
50
 where males were more in number. 
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In this study there was a statistically significant reduction in the frequency of 
diarrhoea within the groups. This shows that both therapies were effective in reducing the 
frequency of diarrhoea. On comparing synbiotic with probiotics on day 3, there was a 
statistically significant reduction in the frequency of diarrhoea(p< 0.02). This may 
probably be due to the effect of synbiotic in reducing the frequency of diarrhoea.  
There was a statistically significant reduction in the duration of diarrhoea on 
comparing synbiotics with probiotics (p<0.001). This shows that the reduction in duration 
of diarrhoea may be due to the effect of synbiotic.  This is in  correlation with the  studies 
conducted by  Allen SJ (2004) , Dhingra U, Malik (2006)  and  Szajewska ( 2007)  which 
also showed  similar  reduction of frequency and duration by adding synbiotics.
51,52,53
  
 There was no statistically significant difference in hematological parameters 
(RBC count, Total count , Differential count, Hemoglobin , Platelet count), renal function 
test  (Blood Sugar, Blood Urea and Serum creatinine , Serum electrolytes) and Liver 
function test (Serum SGOT ,Serum SGPT) within the groups. This shows that Synbiotic 
and Probiotic did not have any effect on the haematological and biochemical lab 
parameters. This is similar to the results of study done by Robert John Boyle et al,
54 
which 
also showed that Synbiotic did not affect haematological and biochemical lab parameters. 
 No serious adverse effects were reported in this study. All the Adverse Drug 
Reactions recorded were categorized as possible under WHO causality assessment scale. 
According to the Modified Hartwig and Siegel severity assessment scale all the adverse 
reactions reported were mild. There was no significant difference in the occurrence of 
adverse effects between the two groups suggesting that addition of synbiotics and 
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probiotics is not associated with increase in the incidence of adverse reactions. This was in 
correlation with the studies conducted by Boyle et al
54  
and Basu et al
55
 where addition of 
Synbiotics did not increase the frequency or severity of Adverse Drug Reactions. 
 
 .   
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CONCLUSION 
 
From this study we conclude that  
 Synbiotic is effective in reducing the frequency of diarrhoea. 
 Synbiotic is effective in reducing the duration of diarrhoea 
 Synbiotic is well tolerated. 
When administered along with standard therapy in children with acute diarrhoea, 
the possible mechanism being maintenance of intestinal barrier function and 
stimulation of host immunity. 
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APPENDICES 
 
APPENDIX-I 
LIST OF ABBREVIATIONS USED 
 
ADR   –  Adverse Drug Reaction 
HLA   –  Human Leukocyte Antigen 
ORS                _          Oral rehydration solution 
ORT               _          Oral rehydration Therapy 
i.v   – Intravenous 
EHEC   –  Enterohemorrhagic 
AAD              _           Antibiotic Associated diarrhoea 
IBS  – Irritable Bowel syndrome 
IBD       – Inflammatory Bowel disease 
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                                                 APPENDIX -II 
 
 CASE REPORT FORM 
A randomized, open label, comparative study of Multi-strained synbiotic against single strained 
probiotic in children with acute diarrhoea 
NAME           :                                        
 
AGE/SEX       :                 
 
WEIGHT        : 
 
PLACE           : 
 
OP NO           : 
 
DIAGNOSIS   :   
 
 
VISIT 1 
1 .Vitals: 
 
2. Medical History: 
 
99 
 
 
3. General /systemic examination: 
 
 
4. Investigations: 
 
Complete blood count : 
 
 
 
 
Serum electrolytes : 
 
Blood urea:  
 
Serum Creatinine : 
 
 
VISIT 2 
1 .Vitals: 
 
2. Medical History: 
 
100 
 
 
 
3. Investigations: 
 
        Complete blood count : 
 
Serum electrolytes : 
 
Blood urea:  
 
Serum Creatinine : 
 
 
4. Adverse Events: 
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APPENDIX-111 
  
Information to Participants 
Title:    “A Randomized, Open label, Comparative study of multi-strained synbiotic against single 
strained probiotic in acute diarrhoea in children ” 
 
Principal Investigator:  
 
Name of Participant: 
 
This study is being conducted in the Diarrhoea OPD and ward,institute of Child Health, Chennai. 
You are invited to take part in this study. The information in this document is meant to help you 
decide whether or not to take part. Please feel free to ask if you have any queries or concerns. 
 
Acute Gastroenteritis is one of the most and frequent disease in the childhood, considering the 
advances in treatment, Lactobacillus has being well described as a probiotic which reduces the 
number of days of hospitalization and also the severity. The overall goal of this study is to 
investigate whether the modulatory effects of multi strained synbiotics is more effective than 
single strained Probiotic, in the gastrointestinal tract  in restoration of intestinal function.We want 
to test the efficacy and safety of treatment with Multi-strained synbiotic in this condition.  
102 
 
We have obtained permission from the Institutional Ethics Committee.  
 
The study design 
All patients in the study will be divided into 2 groups A & B. You will be assigned to either of the 
groups. Group A will receive standard treatment + multi-strained synbiotic & Group B will receive 
standard treatment + single strained probiotic. 
 
Study Procedures 
The study involves evaluation of safety and efficacy of synbiotic against probiotic. The planned 
scheduled visits involve visits at 1st and 7th day of the  week . You will be required to visit the 
hospital 2 times during the study.  
At each visit, the study physician will examine you. Blood tests will be carried out once during the 
study  and  about  5 ml blood will be collected. These tests are essential to monitor your 
condition, and to assess the safety and efficacy of the treatment given to you. 
In addition, if you notice any adverse events, you have to report it. You will be required to return 
unused study medicines when you report for your scheduled visits. This will enable correct 
assessment of the study results. 
Possible benefits to you – synbiotic along with standard treatment will provide faster recovery in 
your children 
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 Possible benefits to other people - The results of the research may provide benefits to the 
society in terms of advancement of medical knowledge and/or therapeutic benefit to future 
patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information (personal 
details, results of physical examinations, investigations, and your medical history). By signing this 
document, you will be allowing the research team investigators, other study personnel, sponsors, 
Institutional Ethics Committee and any person or agency required by law like the Drug Controller 
General of India to view your data, if required.The information from this study, if published in 
scientific journals or presented at scientific meetings, will not reveal your identity. 
Your decision not to participate in this research study will not affect your medical care or your 
relationship with the investigator or the institution. You will be taken care of  and you will not 
loose any benefits to which you are entitled.  
The participation in this research is purely voluntary and you have the right to withdraw from this 
study at any time during the course of the study without giving any reasons. However, it is 
advisable that you talk to the research team prior to stopping the treatment/discontinuing of 
procedures etc. 
 
Signature of Investigator                            Signature of Parent/ Guardian   
 
Date                                                                                      
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APPENDIX-1111 
 
  INFORMED CONSENT FORM 
 A  randomised open label, comparative study of Multi-strained synbiotic  against single 
strained probiotic in children with acute diarrhoea. 
 
Name of the Participant: 
I _____________________________ have read the information in this form (or it has been read 
to me). I was free to ask any questions and they have been answered. I am over 18 years of age 
and, exercising my free power of choice, hereby give my consent that my child be included as a 
participant in this study. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out my child of the study at any time without having to 
give any reasonand this will not affect my future treatment in this hospital.  
6. I hereby give permission to the investigators to release the information obtained from me as 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and 
IEC.Iunderstand that they are publicly presented. 
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7. I have understand that my identity will be kept confidential if my data are publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided my child to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. By 
signingthis consent form I attest that the information given in this document has been clearly 
explained to meand understood by me, I will be given a copy of this consent document. 
 
 
1.Name and signature / thumb impression of the Parent/ Guardian  
 
Name ___________________  Signature_________________ Date_______ 
 
 
2.Name and Signature of impartial witness (required for illiterate patients): 
 
Name ______________________ Signature_________________ Date_______ 
 
Address and contact number of the impartial witness: 
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Name and Signature of the investigator or his representative obtaining consent: 
 
 
Name _____________________ Signature_________________ Date_______ 
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